Angina Pectoris News and Research RSS Feed - Angina Pectoris News and Research

New generation drug eluting stents show lower efficacy than contemporary BMS, study shows

New generation drug eluting stents show lower efficacy than contemporary BMS, study shows

New generation drug eluting stents (new DES) did not outshine contemporary bare metal stents (BMS) as they were expected to, in a surprise finding of the largest randomized stent trial to date. [More]
miRNAs may improve risk prediction in CAD

miRNAs may improve risk prediction in CAD

Single microRNAs derived from peripheral blood predict cardiovascular mortality in patients with coronary artery disease, German research shows. [More]
Ticagrelor drug shows minor added benefit for patients with history of myocardial infarction

Ticagrelor drug shows minor added benefit for patients with history of myocardial infarction

The German Institute for Quality and Efficiency in Health Care assessed the added benefit of ticagrelor for patients with acute coronary syndrome already in 2011 in its very first dossier assessment, just after the Act on the Reform of the Market for Medicinal Products had come into force. [More]
Aralez resubmits NDA package for YOSPRALA to FDA

Aralez resubmits NDA package for YOSPRALA to FDA

Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. [More]
Sleeping too much or too little increases risk of dying from heart disease

Sleeping too much or too little increases risk of dying from heart disease

Too much or too little sleep is linked with an increased risk of certain types of cardiovascular disease. Women and the elderly are particularly at risk.Sleeping less than four hours or more than eight hours a night increases the risk of dying from some types of coronary heart disease, such as heart attacks and unstable angina pectoris, according to a study by Norwegian and Taiwanese researchers. [More]
FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients. [More]
Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Four-year results for an ongoing study of second-line bosutinib indicate that the tyrosine kinase inhibitor offers long-term efficacy with manageable side effects for patients with chronic phase chronic myeloid leukaemia. [More]
New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients. [More]
Full clinical trial feasible in refractory chronic angina pectoris

Full clinical trial feasible in refractory chronic angina pectoris

Results of the world's first publicly funded randomized controlled clinical trial of spinal cord stimulation, being presented today at the 12th World Congress of the International Neuromodulation Society, conclude that a fully powered clinical trial is feasible in refractory chronic angina pectoris, a disabling and persistent chronic pain condition. [More]
Antihypertensive therapy decreases risk of mortality, CV events, strokes in older adults

Antihypertensive therapy decreases risk of mortality, CV events, strokes in older adults

Antihypertensive therapy reduces the risk of cardiovascular (CV) events, strokes and mortality in hypertensive older adults, according to research presented at ESC Congress 2014 today by Dr Maciej Ostrowski from Poland. [More]
Cardium announces review in Journal of Cardiovascular Pharmacology finds gene therapy for subset of heart disease patients ‘highly warranted’

Cardium announces review in Journal of Cardiovascular Pharmacology finds gene therapy for subset of heart disease patients ‘highly warranted’

Cardium Therapeutics, an operating unit of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) has announced the publication of a review article in the Journal of Cardiovascular Pharmacology that concludes a gene therapy product promoting the growth of blood vessels is “highly warranted” to treat about 1 million U.S. heart-disease patients and 6 million more worldwide who are either ineligible or poor candidates for traditional angioplasty, stent placement or bypass surgery. [More]
Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. [More]
Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week. [More]
Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo International plc announced today that affiliates of the company have completed the acquisition of worldwide rights to Sumavel® DosePro® (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc, for $85 million in cash and rights to additional cash payments based on the achievement of certain commercial milestones. [More]
Treating long wait-times dictate long-term success of spinal cord stimulation therapy

Treating long wait-times dictate long-term success of spinal cord stimulation therapy

Success rates soared to 75% for patients who waited less than 2 years for a spinal cord stimulator (SCS) implant, compared with 15% for patients whose implants happened 20 years after the onset of pain, according to a retrospective analysis. [More]
POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2013. [More]
Long-term exposure to particulate matter linked with increased risk for heart attack

Long-term exposure to particulate matter linked with increased risk for heart attack

Long-term exposure to particulate matter is associated with an increased risk for heart attack. Moreover, this association can already be observed in levels of particulate exposure below the current specified European limit values. [More]
Psychotic symptoms alone denote medical health risk

Psychotic symptoms alone denote medical health risk

People with symptoms of psychosis have an increased rate of medical comorbidities and unhealthy lifestyle habits even if they do not have a psychiatric diagnosis, shows a worldwide study. [More]
High-intensity exercise protective against coronary heart disease

High-intensity exercise protective against coronary heart disease

High-intensity exercise is shown to be protective against coronary heart disease and is well known as a popular and time-saving approach to getting fit. But what about people who already have heart disease? Previously, these patients were told to exercise, but only at a moderate intensity to protect their hearts. More recently, however, researchers have found that high-intensity exercise is very beneficial for these patients. [More]
Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Sanofi US and POZEN Inc. announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet ("PA"), PA8140 and PA32540. [More]
Advertisement
Advertisement